Teachers Retirement System of The State of Kentucky Buys 17,343 Shares of BridgeBio Pharma, Inc. $BBIO

Key Points

• Teachers Retirement System of Kentucky increased its stake in BridgeBio by 159.6%, buying 17,343 shares and now owning 28,211 shares valued at about $2.16 million per the latest SEC filing.
• BridgeBio reported Q2 EPS of -$1.00 (missing estimates by $0.25) while revenue of $154.18 million beat expectations with a >2,500% YoY increase; the stock opened near $69.75 and was down 6.4% on the day.
• Insiders have sold aggressively—237,084 shares worth roughly $16.63 million in the last quarter—yet institutional ownership is very high (99.85%) and analysts remain largely bullish (24 Buys, 1 Sell; average price target ≈ $87.38).

Teachers Retirement System of The State of Kentucky grew its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 159.6% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 28,211 shares of the company's stock after buying an additional 17,343 shares during the quarter. Teachers Retirement System of The State of Kentucky's holdings in BridgeBio Pharma were worth $2,158,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of BBIO. Aster Capital Management DIFC Ltd bought a new stake in shares of BridgeBio Pharma during the third quarter worth $31,000. Harvest Fund Management Co. Ltd bought a new stake in shares of BridgeBio Pharma during the third quarter worth $34,000. Jones Financial Companies Lllp bought a new stake in shares of BridgeBio Pharma during the first quarter worth $35,000. First Horizon Corp bought a new stake in shares of BridgeBio Pharma during the third quarter worth $36,000. Finally, Huntington National Bank grew its stake in shares of BridgeBio Pharma by 111.7% during the third quarter. Huntington National Bank now owns 743 shares of the company's stock worth $39,000 after buying an additional 392 shares during the last quarter. Institutional investors own 99.85% of the company's stock.

BridgeBio Pharma Stock Down 6.4%

Shares of BridgeBio Pharma stock opened at $69.75 on Wednesday. BridgeBio Pharma, Inc. has a twelve month low of $31.77 and a twelve month high of $84.94. The stock has a market cap of $13.66 billion, a price-to-earnings ratio of -18.45 and a beta of 1.09. The company's fifty day moving average is $71.33 and its 200 day moving average is $70.84.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last issued its quarterly earnings data on Tuesday, February 24th. The company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.25). The company had revenue of $154.18 million for the quarter, compared to the consensus estimate of $150.71 million. During the same quarter last year, the company posted ($1.40) earnings per share. The firm's revenue was up 2521.2% compared to the same quarter last year. As a group, equities analysts anticipate that BridgeBio Pharma, Inc. will post -2.07 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of BridgeBio Pharma in a research note on Wednesday, January 21st. Raymond James Financial set a $89.00 target price on shares of BridgeBio Pharma and gave the stock an "outperform" rating in a research note on Thursday, February 12th. HC Wainwright reissued a "buy" rating and issued a $100.00 price objective on shares of BridgeBio Pharma in a research note on Monday. TD Cowen reissued a "buy" rating on shares of BridgeBio Pharma in a research note on Monday, January 12th. Finally, Truist Financial boosted their price objective on shares of BridgeBio Pharma from $86.00 to $95.00 and gave the stock a "buy" rating in a research note on Wednesday, February 25th. Twenty-four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, BridgeBio Pharma has an average rating of "Moderate Buy" and an average price target of $87.38.

Key Stories Impacting BridgeBio Pharma

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Mizuho reaffirmed an "outperform" rating and set a $106 price target, signaling analyst conviction and a sizable upside vs. the current level; this supports buyer interest. Mizuho Outperform / $106 PT
• Positive Sentiment: HC Wainwright reiterated a "buy" rating with a $100 price target, another bullish analyst endorsement that can underpin the stock. HC Wainwright Buy / $100 PT
• Positive Sentiment: BridgeBio announced a settlement with Pfizer in the Vyndamax patent dispute — removing litigation uncertainty could be a material de‑risking event, though market reaction has been mixed. BridgeBio seesaws after settlement in Pfizer Vyndamax patent dispute (update)
• Neutral Sentiment: BridgeBio posted its Q2 2025 earnings transcript — contains operational and management commentary investors will parse for guidance and program updates; read for specifics on sales and R&D cadence. BridgeBio (BBIO) Q2 2025 Earnings Transcript
• Neutral Sentiment: BridgeBio launched a health education campaign featuring high‑profile advocates (Morgan Freeman, Howard H. White) — positive PR but unlikely to move valuation materially in the short term. BridgeBio Launches Health Education Effort
• Neutral Sentiment: Market commentary asking whether it's "too late" to buy after a one‑year surge — useful framing for investors assessing momentum and valuation, but not news that directly alters fundamentals. Is It Too Late To Consider BridgeBio Pharma (BBIO)?
• Negative Sentiment: A headline ties BBIO to a Pfizer connection while noting the stock is on track for its worst day in months — negative headlines and headline volatility can prompt sell pressure even if underlying news is mixed. BBIO on track for worst day in 2.5 months
• Negative Sentiment: A Zacks preview warns BridgeBio lacks the setup for an earnings beat this quarter — expectations of another negative EPS print or guidance misses can pressure the stock. Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings?

Insider Buying and Selling

In related news, CFO Thomas Trimarchi sold 13,600 shares of the business's stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $74.72, for a total value of $1,016,192.00. Following the transaction, the chief financial officer owned 336,585 shares in the company, valued at $25,149,631.20. The trade was a 3.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Maricel Apuli sold 510 shares of the company's stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $74.31, for a total transaction of $37,898.10. Following the sale, the chief accounting officer directly owned 123,945 shares in the company, valued at $9,210,352.95. This trade represents a 0.41% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 237,084 shares of company stock valued at $16,634,419 over the last quarter. 18.20% of the stock is currently owned by company insiders.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio's pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.

Want to see what other hedge funds are holding BBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.